STUDY OF THE ANTITUMOR ACTIVITY OF ISOLIQUIRITIGENIN ON THE HELA, PC3, AND MCF-7 TUMOR CELL LINES

Abstract

In 2020, the most common type of malignancy was breast cancer. According to WHO, in 2020, this type of cancer accounted for one in eight new cases of cancer in the world and one in four – among women: this disease was diagnosed in 2.3 million people. One of the factors influencing a high mortality rate among patients with this diagnosis can be attributed to an increase in the level of tumor cells resistance to the chemotherapeutic preparations used, so today it is extremely important to search for new preparations that have high specificity for malignant neoplasms, low toxicity and availability for patients. In this regard, a lot of researchers' attention is attracted by compounds of natural origin, in particular the group of flavonoids, which includes isoliquiritigenin. According to the results of modern studies, this compound can have antitumor activity in vitro and in vivo, affecting the molecular mechanisms of regulating the growth and survival of tumor cells. The aim of this article is to study the antitumor antiproliferative activity of isoliquiritigenin on the HeLa, PC-3, and MCF-7 tumor cells lines in vitro. The antiproliferative activity was evaluated using the MTT test with the exposure of cells with the test compound for 72 hours. As a result of the study, isoliquiritigenin showed a dose-dependent antiproliferative effect on human tumor lines PC-3, MCF-7 in the concentration range 10–4–2,5×10–5 mol/l.